Basic Doxepin Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In Canada (English): not specified
• ATC Code: e.g., N02BE01
• Forms & Dosages: Tablet (325mg, 500mg, 650mg); Caplet (500mg); Oral Suspension (120mg/5ml, 250mg/5ml); Suppository (125mg, 250mg, 500mg); Effervescent Tablet (500mg, 1000mg); Intravenous Solution (10mg/ml)
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: OTC in most markets; prescription-only in select combinations or high-dose formulations

Key Findings From Recent Trials

Which trial results matter if you or a patient asks about doxepin now?

Major randomized controlled trials and pooled analyses from 2022–2024 emphasise low‑dose doxepin for sleep maintenance and reconfirm older evidence for antidepressant uses.

Canadian pharmacoepidemiology reports (2022–2023) and international cohort studies consistently link tricyclic antidepressants to higher anticholinergic burden and greater fall and cognitive risk in older adults, and doxepin appears in several of those signal analyses.

Small RCTs and pooled insomnia data show low‑dose doxepin (3–6 mg) improves sleep maintenance versus placebo with better daytime functioning compared with many sedative‑hypnotics in short trials.

For major depression, recent network meta‑analyses reconfirm doxepin’s efficacy is comparable to other TCAs, with higher anticholinergic and orthostatic adverse effects compared with SSRIs.

Primary outcomes across studies: modest‑to‑large improvements in sleep maintenance at low doses and similar remission rates for depressive disorder when compared head‑to‑head with other TCAs.

Safety observations emphasise anticholinergic effects, orthostatic hypotension, potential QT prolongation at higher doses, and overdose lethality risk, with Canadian geriatric guidance urging patient‑level risk stratification.

Clinical Mechanism Of Action

How does doxepin work in simple terms?

Doxepin is a tricyclic antidepressant that increases serotonin and norepinephrine activity and blocks histamine H1 receptors.

At antidepressant doses it modulates mood circuits over weeks, while at very low doses (3–6 mg) it acts mainly as a potent H1 antagonist to improve sleep maintenance with minimal antidepressant transporter effects.

What does the science say in more detail?

Doxepin hydrochloride inhibits reuptake of norepinephrine and serotonin by blocking their transporters, producing antidepressant and anxiolytic effects after several weeks of treatment.

The drug has high affinity for central H1 receptors, and at sub‑antidepressant doses the H1 blockade reduces nocturnal wakefulness without significant noradrenergic or serotonergic modulation.

Pharmacokinetics

Absorption: well absorbed orally with Tmax around 2–4 hours.

Metabolism: hepatic via CYP450 enzymes (notably CYP2D6) to active metabolites such as nordoxepin.

Elimination: renal and hepatic pathways; long half‑life (approximately 18–32 hours) leads to steady state over days.

Pharmacodynamics

Multireceptor profile: H1 antagonism is dominant at low doses, while antimuscarinic and alpha‑1 antagonism emerge at higher doses, producing anticholinergic effects that correlate with dose.

Scope Of Approved And Off‑Label Use

What is doxepin officially approved for, and how do clinicians use it off‑label?

In Canada, doxepin is approved consistent with the tricyclic antidepressant class for depressive disorders and some neuropathic indications, and marketed formulations carry assigned DINs when available.

Low‑dose doxepin products marketed in the United States for insomnia (Silenor 3 mg and 6 mg) have limited marketed presence in Canada, and prescribers may use low‑dose tablets off‑label or order compounded preparations when appropriate.

Notable off‑label trends in Canadian practice include topical doxepin for chronic pruritus in selected jurisdictions, low‑dose oral doxepin for insomnia, and adjunctive use for neuropathic pain or chronic urticaria when other options have failed.

Canadian dermatology, psychiatry, and sleep medicine specialists increasingly prefer evidence‑based, lower‑anticholinergic alternatives for older adults, but low‑dose doxepin remains an option when alternatives are unsuitable or not tolerated.

Dosage Strategy

How is doxepin dosed for different conditions and patient groups?

Antidepressant dosing per Health Canada monographs generally ranges from 75–300 mg per day, given in divided doses or as a single nightly dose depending on tolerance and clinical indication.

Start low and titrate cautiously, watching for orthostatic hypotension and anticholinergic effects; typical adult initiation is 10–25 mg daily with escalation over 1–2 weeks guided by response and side effects.

Condition‑specific choices:

• Insomnia (low‑dose strategy): 3–6 mg at bedtime to target sleep maintenance while minimising systemic TCA effects; this is commonly used off‑label in Canada when Silenor is not available.
• Neuropathic pain: lower antidepressant‑range dosing (25–100 mg/day) with gradual titration balancing analgesic effect and tolerability.
• Elderly and hepatic impairment: reduce dose by roughly 25–50%, extend titration intervals, and consider alternatives if anticholinergic burden is high.

Pediatric dosing is limited and should follow specialist guidance and any DIN‑labelled instructions when present.

Safety Protocols

Who should not take doxepin, and what should pharmacists monitor?

Absolute contraindications include recent myocardial infarction, known hypersensitivity to doxepin, concurrent or recent monoamine oxidase inhibitor (MAOI) therapy, and severe uncontrolled narrow‑angle glaucoma or urinary retention due to anticholinergic effects.

Use in pregnancy requires caution and should only proceed if benefits outweigh risks, with obstetrical and psychiatric teams involved.

Common adverse effects reported post‑market include dry mouth, constipation, blurred vision, urinary retention, sedation, weight gain, and orthostatic hypotension.

Serious reactions include cardiac conduction abnormalities such as QT prolongation and widened QRS complexes, seizures at high doses, and significant anticholinergic cognitive impairment in older adults.

Canadian post‑market surveillance highlights anticholinergic burden and falls in frail seniors, and pharmacovigilance advisories recommend minimising use in the elderly when possible.

Monitoring Recommendations

Perform baseline ECG for patients with cardiac risk, check renal and hepatic function, reconcile medications for anticholinergic load, and assess suicide risk when prescribing for depression.

Interaction Mapping

Which foods, supplements, and drugs interact with doxepin?

There are no major food interactions, although high‑fat meals may delay the time to peak concentration (Tmax).

Alcohol should be avoided because it adds sedation and may worsen other side effects; herbal sedatives such as melatonin or valerian can potentiate somnolence.

Health Canada flags several high‑risk drug combinations including concurrent MAO inhibitors (contraindicated) and other serotonergic agents that raise serotonin syndrome risk.

Potent CYP2D6 inhibitors such as fluoxetine and paroxetine can increase doxepin plasma levels and adverse effects, so dose reduction or monitoring may be required.

Combining doxepin with other QT‑prolonging drugs (for example certain macrolide antibiotics or antipsychotics) elevates cardiac risk, and concurrent anticholinergic drugs increase cognitive and fall risks, especially in elderly patients.

Practical Pharmacist Checks

Reconcile prescription and OTC medications at each refill, flag CYP2D6 inhibitors, counsel on avoiding alcohol and sedative supplements, and document monitoring plans for high‑risk combinations.

Patient Experience Analysis

What do Canadian patients say about doxepin in clinics and pharmacies?

Surveys from primary care and psychiatric clinics (2021–2024) show mixed satisfaction: many patients on low‑dose regimens report meaningful improvements in sleep maintenance, while those on antidepressant doses note effective mood control but more frequent dry mouth, daytime sedation and orthostatic symptoms.

Older patients commonly report cognitive blunting or episodes of dizziness leading to falls, prompting deprescribing initiatives in geriatric care settings.

Community pharmacy feedback from national chains indicates frequent patient interest in switching from SSRIs to TCAs for partial response and particular curiosity about low‑dose options for sleep problems.

Online forums and community discussions often highlight concerns about daytime grogginess and anticholinergic side effects, and pharmacists routinely advise slow titration, bedtime dosing, and comprehensive medication reviews for people taking multiple drugs.

Distribution And Pricing Landscape

Where can Canadians get doxepin, and what should they expect to pay?

Doxepin tablets are commonly stocked across major Canadian pharmacy chains such as Shoppers Drug Mart, Rexall, Jean Coutu and London Drugs, with varying brand availability including generic formulations.

Generic doxepin is typically lower cost and pharmacies often carry multiple strengths that allow low‑dose regimens to be achieved by tablet splitting or pharmacy compounding when appropriate.

Canadian online pharmacies dispense doxepin with a prescription and validate DINs as part of the dispensing process, and provincial e‑prescribing and telepharmacy options have made lawful access more convenient.

Out‑of‑country mail orders may sometimes show lower list prices, but Health Canada advises caution over regulatory, formulation and dosing differences when ordering cross‑border.

In our online pharmacy, doxepin is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Alternative Options

What are DIN‑approved alternatives and how do they compare to doxepin?

Available alternatives include:

• SSRIs (e.g., sertraline, escitalopram): first‑line for depression with lower anticholinergic risk compared with TCAs.
• SNRIs (e.g., venlafaxine, duloxetine): useful for depression and neuropathic pain, and often preferred when analgesic benefit is sought.
• Mirtazapine: sedating antidepressant helpful for sleep and appetite stimulation, but carries a weight gain risk.
• Z‑drugs, trazodone and low‑dose doxepin: pharmacologic options for insomnia; choice depends on comorbidity, fall risk and anticholinergic profile.

Pros of doxepin: effective for depression, helpful at very low doses for sleep maintenance, useful in neuropathic pain settings, and generally low cost as a generic medication.

Cons of doxepin: anticholinergic burden, orthostatic hypotension, cardiac risk at higher doses, and suitability concerns in frail elderly or highly medicated patients.

Regulatory Status

How is doxepin regulated in Canada and what labelling rules apply?

Doxepin hydrochloride is an approved active substance in Canada when a product has an assigned DIN and meets Health Canada requirements for safety, efficacy and manufacturing standards.

Regulatory review is ongoing and label updates follow post‑market evidence, with Health Canada issuing advisories when new safety signals emerge—particularly around anticholinergic risks in older adults.

All marketed products in Canada must carry a DIN for pharmacy verification and adhere to bilingual labelling rules (English/French) and consumer safety information requirements.

Prescription status: doxepin is prescription‑only in Canada for labeled antidepressant and neurologic indications, and low‑dose sleep claims marketed abroad may not have equivalent approved Canadian claims, leaving off‑label use to clinician discretion with appropriate documentation.

Consolidated FAQ

What are common patient questions about doxepin in Canada?

Q: Is doxepin approved in Canada for insomnia?

A: Low‑dose sleep formulations are primarily US‑branded; in Canada clinicians may prescribe low doses off‑label, and pharmacists should check DINs and product monographs for details.

Q: Is doxepin safe for older adults?

A: Use caution—anticholinergic effects increase fall and cognitive risk in seniors, so consider alternatives or the lowest effective dose with structured monitoring.

Q: Can I drink alcohol while taking doxepin?

A: Avoid alcohol because it adds sedation and can increase adverse effects.

Q: Will my provincial drug plan cover doxepin?

A: Coverage varies by DIN and indication; check provincial formularies such as Ontario Drug Benefit (ODB), BC PharmaCare and RAMQ for Quebec for specific DIN coverage and special authorization requirements.

Q: What should I do in an overdose?

A: Seek emergency care immediately; tricyclic antidepressants can cause cardiotoxic and neurologic overdose features requiring hospital monitoring and supportive treatment.

Visual Guide

What should go into simple patient and clinician visuals for doxepin?

Dosage infographic: split lanes for insomnia (3–6 mg), depression (75–300 mg) and neuropathic dosing (25–100 mg), plus elderly adjustments and titration steps.

Provincial coverage map: highlight differences in ODB, BC PharmaCare and RAMQ formularies and recommend DIN lookup per province.

Purchase channels flowchart: prescription → community pharmacy chains (Shoppers/Rexall/Jean Coutu/London Drugs) → provincial e‑pharmacy → cross‑border risks and cautions.

Safety checklist graphic: baseline ECG for high‑risk patients, medication reconciliation, orthostatic BP check, and an anticholinergic burden score such as the Anticholinergic Cognitive Burden scale.

Design notes: use Health Canada‑aligned colours, bilingual labels where possible, accessible text alternatives, and conservative clinical icons for patient handouts and pharmacist counselling prompts.

Storage And Transport

How should doxepin be stored at home and handled during travel?

Store doxepin oral tablets at room temperature, ideally between 15–25°C, away from moisture and direct heat, and keep them in the original labelled container with child‑resistant cap.

Do not flush unused tablets; return them to a pharmacy take‑back program or follow local municipal hazardous waste disposal instructions.

Oral doxepin tablets do not require cold chain storage.

Compounded low‑dose liquids may have pharmacy‑specific instructions and could require refrigeration if preservative‑free, so follow the label on dispensed products.

For transport, keep medications in secure packaging and carry the pharmacy label and prescription when flying to comply with Canadian Air Transport Authority and border rules.

Pharmacies should provide storage counselling, expiry checks and bilingual instructions, and advise patients to take doxepin at bedtime and avoid operating machinery until response and tolerance are verified.

Guidelines For Proper Use

What practical steps should pharmacists and prescribers follow to use doxepin safely?

Advice from Canadian pharmacists: start low and titrate slowly, counsel on interactions with CYP2D6 inhibitors and other sedatives, and emphasise the anticholinergic risk, especially in older patients.

Avoid abrupt discontinuation; provide a taper plan to minimise withdrawal symptoms and coordinate medication reviews across prescribers and provincial drug programs.

Provincial health authority guidance generally recommends minimising anticholinergic medications in seniors and documenting clinical rationale when a TCA is necessary.

For insomnia, recommend cognitive behavioural therapy for insomnia (CBT‑I) as first‑line care and consider low‑dose doxepin only when non‑pharmacologic measures are insufficient or not available.

Practical Checklist

• Confirm indication and DIN when dispensing.
• Reconcile all medications for anticholinergic load.
• Obtain baseline ECG for patients with cardiac risk factors.
• Provide a bilingual counselling sheet and follow‑up plan within 1–4 weeks of starting therapy.

Delivery Across Canada (English)